A child health initiative targeting preventable diseases in northern Nigeria has delivered over 26 million doses of azithromycin to children aged one to 59 months across ten states between 2024 and early 2026. The Safety and Antimicrobial Resistance of Mass Administration of Azithromycin in Nigeria (SARMAAN) Project reached 15.76 million children during this period, with more than 7.2 million treated in the first quarter of 2026 alone in Kano, Bauchi, Jigawa and Kaduna states. Led by the Nigerian Institute of Medical Research, the project forms part of the regional REACH network aimed at reducing under-five mortality. Principal investigator Oliver Ezechi stated, "Reaching over 15 million children shows what is possible when global priorities meet local action." The programme combines drug distribution with community engagement to build trust and encourage sustained health-seeking behaviour. Despite progress, sustainability remains uncertain due to reliance on donor funding. Ikechukwu Ofuani, who leads advocacy for SARMAAN, emphasized that "true impact is what can be sustained tomorrow," urging integration into national health budgets and policies. Nigeria continues to face one of the highest under-five mortality rates globally, underscoring the importance of scalable, locally owned health interventions.
The SARMAAN Project's reach of 15.76 million children proves large-scale health interventions can work even in high-burden areas, but its dependence on donor funding exposes a recurring flaw in Nigeria's public health strategy. Oliver Ezechi's assertion that global priorities and local action can yield results rings true—yet without government commitment to fund and absorb such efforts, gains risk unraveling once external support fades. This isn't about replicating a programme; it's about whether Nigeria's health system can evolve beyond pilot projects into sustained, domestic delivery. For Nigerian children, the difference between survival and preventable death may hinge less on medicine than on political will to fund what already works.
